RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+0.84%Aug 21, 2026, 12:30 UTC
RenovoRx received written notification from Nasdaq confirming it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Source:Aug 17, 2026, 01:02 UTC
RenovoRx announced that its RenovoCath delivery device has expanded to 21 centers, indicating commercialization progress.
Source:Aug 12, 2026, 20:05 UTC
RenovoRx delivered the first treatment with RenovoCath in a patient with sarcoma in a clinical setting, marking expansion of the device to other solid tumors.
Source:Aug 12, 2026, 20:05 UTC
RenovoRx's Phase III TIGeR-PaC trial reached full enrollment; completion of the trial is expected in the first half of 2027 with topline data readout expected in the second half of 2027.
Source:Aug 12, 2026, 20:05 UTC
RenovoRx reported record second quarter 2026 results with 61% sequential quarterly revenue growth and raised its 2026 annual revenue guidance to a range of $3.75M to $4.25M.
Aug 6, 2026, 12:30 UTC
RenovoRx announced the first commercial clinical use of its RenovoCath device in treating a sarcoma patient at CARTI Cancer Center, expanding the device's application to other solid tumors.
Source: